CD79B and neoplasm: The analysis of CD79B expression and clinicopathological factors demonstrated that CD79B expression was related to primary therapy outcome, race, histological type, the degree of differentiation, disease-specific survival, and progression-free interval, whereas there was no statistically significant correlation between CD79B expression and age, tumor depth, distant metastasis, lymph node metastasis, clinical stage, histologic grade, radiation therapy, orBMI.